Company intelligence / Profile preview

Visterra

Waltham, Massachusetts, United Statesx.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Visterra has a clinical-stage pipeline including VIS410 for influenza A which received FDA Fast Track Designation and entered Phase 2a trials in January 2017. They also have VIS705 in development for infectious diseases.

Therapeutic areas: Infectious DiseasesNephrology
Modalities: Antibody-based therapies
Industry: Biotech

Drug pipeline

8 assets

VIS410

7 more assets in the full pipeline.

Request access →

Partnerships

Vir Biotechnology (research collaboration, exclusive license, and option agreement for infectious diseases)

Beyond the preview

Go deeper on Visterra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visterra.

Explore the full profile